Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01SCR
|
|||
| Former ID |
DIB011658
|
|||
| Drug Name |
NPB-001-056
|
|||
| Synonyms |
KM-80; NPB-001-05; Bcr-abl kinase inhibitor (oral, cancer), Piramal Life Sciences; Bcr-abl kinase inhibitor(oral, cancer), NPIL Research & Development
Click to Show/Hide
|
|||
| Indication | Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.1; ICD-9: 205.1] | Phase 1/2 | [1] | |
| Company |
Piramal Healthcare Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033940) | |||
| REF 2 | NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.